TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7522529

Group type: EXPERIMENTAL
Intervention: Sensitive immunoradiometric assays (IRMA)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD) followed by successful renal transplantation
Number of subjects: 127

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 127
Study: 3789755

Group type: EXPERIMENTAL
Intervention: Radiotherapy and/or combination chemotherapies (ACOP, ACOP‐E and AclBEP regimens)
Number of subjects: 92
Study: 29304735

Group type: EXPERIMENTAL
Intervention: IV dexmedetomidine 0.5 μg.kg‐1 (Group DEX, n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: IV saline (Group P, n=30)
Number of subjects: 60
Study: 28031021

Group type: EXPERIMENTAL
Intervention: Adaptability treadmill training
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Conventional treadmill training
Number of subjects: 70

Group type: COMPARATOR
Intervention: Usual physical therapy
Number of subjects: 70
Study: 23736797

Group type: EXPERIMENTAL
Intervention: Interferon therapy
Number of subjects: 45
Study: 22429373

Group type: EXPERIMENTAL
Intervention: Thrombin‐added haemostatic matrix (THM)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Electrocautery plus hot compressor application
Number of subjects: 50
Study: 20384528

Group type: EXPERIMENTAL
Intervention: Terlipressin (2 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 18343242

Group type: EXPERIMENTAL
Intervention: Test formulation (30 mg nifedipine)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Reference formulation (30 mg nifedipine)
Number of subjects: 12
Study: 15928362

Group type: EXPERIMENTAL
Intervention: Psychological treatment
Number of subjects: 257
Study: 11673340

Group type: EXPERIMENTAL
Intervention: Patients with depression (n=380)
Number of subjects: 804

Group type: COMPARATOR
Intervention: Patients without depression (n=424)
Number of subjects: 804

Group type: EXPERIMENTAL
Intervention: Final model analysis (including age, sex, diabetes, present cigarette smoking)
Number of subjects: 804
Study: 9493517

Group type: COMPARATOR
Intervention: Fixed-dose regimen of interferon-alpha2a (3 MIU three times a week for 6 months)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: De-escalating regimen of interferon-alpha2a (6 MIU three times a week for 3 months followed by 3 MIU three times a week for 3 months)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Fixed-dose regimen of interferon-alpha2a (3 MIU three times a week for 6 months) in non-cirrhotic patients
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: De-escalating regimen of interferon-alpha2a (6 MIU three times a week for 3 months followed by 3 MIU three times a week for 3 months) in non-cirrhotic patients
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Overall patients with sustained response
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: ALT activity assessed at month 1
Number of subjects: 291
Study: 8299884

Group type: EXPERIMENTAL
Intervention: High-fat diet (46%)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Low-fat diet (24%)
Number of subjects: 105
Study: 3191075

Group type: EXPERIMENTAL
Intervention: 0.5% timolol
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 2% pilocarpine
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 1% adrenaline
Number of subjects: 26

Group type: COMPARATOR
Intervention: saline
Number of subjects: 26
Study: 7982429

Group type: EXPERIMENTAL
Intervention: L-propionylcarnitine (1.5 g orally for 6 months)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 419810

Group type: EXPERIMENTAL
Intervention: Bencyclane 100 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Bencyclane 200 mg
Number of subjects: 17
Study: 31461548

Group type: EXPERIMENTAL
Intervention: Test regimen (4% niacinamide + Simple® Kind to Skin Moisturizing Facial Wash)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Positive control (4% niacinamide + Neutrogena Visibly Clear® Spot Clearing Facial Wash)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control (no moisturizer + Simple® Kind to Skin Moisturizing Facial Wash)
Number of subjects: 132
Study: 31669451

Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy (VRE) combined with 50 mg D-Cycloserine (DCS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy (PE) combined with 50 mg D-Cycloserine (DCS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy (VRE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy (PE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo combined with Prolonged Exposure Therapy (PE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo combined with Virtual Reality Exposure Therapy (VRE)
Number of subjects: 0
Study: 28357969

Group type: EXPERIMENTAL
Intervention: Lurasidone 20-60 mg/day
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study: 25586864

Group type: EXPERIMENTAL
Intervention: LNG/EE patch (one patch weekly for three consecutive weeks, followed by a patch-free week for 13 cycles)
Number of subjects: 1273

Group type: COMPARATOR
Intervention: Oral contraceptive for six cycles followed by seven LNG/EE patch cycles
Number of subjects: 1273
Study: 24099944

Group type: EXPERIMENTAL
Intervention: 4-gram language model (LM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 3-trial ERP classification
Number of subjects: 0
Study: 21372210

Group type: EXPERIMENTAL
Intervention: Atrasentan 0.75 mg daily
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Atrasentan 1.75 mg daily
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Atrasentan 0.25 mg daily
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 18834823

Group type: EXPERIMENTAL
Intervention: Postoperative red blood cell transfusions
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Maximum white blood cell count
Number of subjects: 550

Group type: COMPARATOR
Intervention: No transfusion
Number of subjects: 550
Study: 17278627

Group type: EXPERIMENTAL
Intervention: Adhesive 1
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Adhesive 2
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Adhesive 3
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Adhesive 4
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: All 4 bonding agents
Number of subjects: 36
Study: 15144613

Group type: EXPERIMENTAL
Intervention: Concurrent treatment group (group A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sequential treatment group (group B)
Number of subjects: 90
Study: 11473503

Group type: EXPERIMENTAL
Intervention: Moclobemide (MCB) 450-750 mg daily
Number of subjects: 156

Group type: COMPARATOR
Intervention: Imipramine (IMI) 150-250 mg daily
Number of subjects: 156

Group type: COMPARATOR
Intervention: Imipramine (IMI)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Moclobemide (MCB)
Number of subjects: 156
Study: 9735587

Group type: EXPERIMENTAL
Intervention: Cognitive bibliotherapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Delayed-treatment control
Number of subjects: 22
Study: 8042735

Group type: EXPERIMENTAL
Intervention: Lignocaine 0.5% via 26-gauge Atraucan spinal needle
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lignocaine 0.5% via 29-gauge Spinocan spinal needle
Number of subjects: 30
Study: 3191076

Group type: EXPERIMENTAL
Intervention: 0.5% timolol
Number of subjects: 6

Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: guanethidine 5% (pretreatment)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: timolol administration to the normal eye
Number of subjects: 6
Study: 30793118

Group type: EXPERIMENTAL
Intervention: GIC sealant with additional light curing
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: GIC sealant without additional light curing
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group (no sealant)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Both sealant groups (A and B)
Number of subjects: 111
Study: 28207733

Group type: EXPERIMENTAL
Intervention: Citalopram (SSRI) administered for 2 weeks
Number of subjects: 0
Study: 25576857

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation at 2500 IU/d during caloric restriction (WL-D)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo during caloric restriction (WL-C)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation at 2500 IU/d during weight maintenance (WM-D)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo during weight maintenance (WM-C)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR)
Number of subjects: 76
Study: 24961093

Group type: EXPERIMENTAL
Intervention: Sodium cromoglicate eye drops combined with Yupingfeng granules
Number of subjects: 118

Group type: COMPARATOR
Intervention: Sodium cromoglicate alone
Number of subjects: 118
Study: 21422420

Group type: EXPERIMENTAL
Intervention: Imatinib 800 mg/d
Number of subjects: 1014

Group type: COMPARATOR
Intervention: Imatinib 400 mg/d
Number of subjects: 1014

Group type: COMPARATOR
Intervention: Imatinib 400 mg/d plus interferon alfa (IFN-α)
Number of subjects: 1014
Study: 19794004

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 57593

Group type: EXPERIMENTAL
Intervention: Statin therapy including WOSCOPS
Number of subjects: 57593
Study: 17068072

Group type: EXPERIMENTAL
Intervention: Alteplase 1 mg/ml
Number of subjects: 9

Group type: COMPARATOR
Intervention: Heparin 5000 U/ml
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Alteplase or urokinase infusion
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Surgical replacements
Number of subjects: 9
Study: 15502051

Group type: EXPERIMENTAL
Intervention: Oxymorphone IR 10 mg
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Oxymorphone IR 20 mg
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Oxymorphone IR 30 mg
Number of subjects: 300

Group type: COMPARATOR
Intervention: Oxycodone IR 10 mg
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 11268301

Group type: EXPERIMENTAL
Intervention: Esterified estrogen (EE)
Number of subjects: 34
Study: 9702441

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 26

Group type: COMPARATOR
Intervention: Amitriptyline plus sham treatment
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Combined electrotherapy and amitriptyline
Number of subjects: 26
Study: 8045488

Group type: EXPERIMENTAL
Intervention: Recombinant interferon‐alpha 2a 7.5 megaunits/m2 three times weekly for 6 mo (group 1)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Recombinant interferon‐alpha 2a on the same schedule (group 2)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Untreated (group 3)
Number of subjects: 77
Study: 2729165

Group type: EXPERIMENTAL
Intervention: Zinc supplement (10 mg Zn/d as ZnSO4)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (boys with hair Zn greater than 1.68 mumol/g)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Zinc supplement
Number of subjects: 60
Study: 31287332

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 867

Group type: COMPARATOR
Intervention: Ustekinumab 45/90 mg
Number of subjects: 867

Group type: COMPARATOR
Intervention: Etanercept 50 mg
Number of subjects: 867
Study: 31189686

Group type: EXPERIMENTAL
Intervention: Percutaneous cryoablation, n=25
Number of subjects: 200

Group type: COMPARATOR
Intervention: Robotic partial nephrectomy, n=25
Number of subjects: 200
Study: 27604107

Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Dipyridamole
Number of subjects: 48
Study: 26348459

Group type: EXPERIMENTAL
Intervention: HIV Pre-Exposure Prophylaxis (PrEP)
Number of subjects: 61
Study: 23934374

Group type: EXPERIMENTAL
Intervention: High-frequency ultrasound (HFU)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Noncontact low-frequency ultrasound (NCLFU)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 90
Study: 21635363

Group type: EXPERIMENTAL
Intervention: Earlier continuous Kangaroo Mother Care (KMC) initiated within 24 hours postbirth
Number of subjects: 72

Group type: COMPARATOR
Intervention: Later continuous Kangaroo Mother Care (KMC) initiated after complete stabilization (control group)
Number of subjects: 72
Study: 18048461

Group type: EXPERIMENTAL
Intervention: Purified Vero cell rabies vaccine (PVRV) given at 2, 4 months and 1 year
Number of subjects: 72

Group type: COMPARATOR
Intervention: Diphtheria, tetanus, whole‐cell pertussis and inactivated poliomyelitis vaccine (DTP‐IPV)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Purified Vero cell rabies vaccine (PVRV) and DTP‐IPV
Number of subjects: 72
Study: 16505510

Group type: EXPERIMENTAL
Intervention: rosiglitazone (4 mg twice a day for 12 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 14655024

Group type: EXPERIMENTAL
Intervention: Insulin + methotrexate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 30
Study: 11389705

Group type: EXPERIMENTAL
Intervention: Dual therapy (with corticosteroids)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Triple therapy (with corticosteroids and azathioprine)
Number of subjects: 345
Study: 9303652

Group type: EXPERIMENTAL
Intervention: Immuno-modulatory nutrition Impact
Number of subjects: 30

Group type: COMPARATOR
Intervention: Precitene Hiperproteico
Number of subjects: 30
Study: 8418030

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 224
Study: 3531958

Group type: EXPERIMENTAL
Intervention: Argon laser photocoagulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 0
Study: 31719071

Group type: EXPERIMENTAL
Intervention: Perineural catheter (PNC) with continuous infusion of levobupivacaine hydrochloride 0.125% for up to 5 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual perioperative anaesthesia and postoperative analgesia (Control)
Number of subjects: 50
Study: 29408444

Group type: EXPERIMENTAL
Intervention: l-arginine (10 mM)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (lactated Ringer's solution)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Arginase inhibited site (5.0 mM BEC and 5.0 mM nor-NOHA)
Number of subjects: 18
Study: 27087145

Group type: EXPERIMENTAL
Intervention: Ivermectin (30 mg oral, once a day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 25060166

Group type: EXPERIMENTAL
Intervention: Diffusion-weighted MR imaging (DWI) and proton magnetic resonance spectroscopy (1H-MRS)
Number of subjects: 30
Study: 23014081

Group type: EXPERIMENTAL
Intervention: Band and loop (B&L) space maintainers
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Direct bonded (DB) space maintainers
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fiber-reinforced composite (FRC) space maintainers
Number of subjects: 30
Study: 20622033

Group type: EXPERIMENTAL
Intervention: Ataluren (PTC124) at lower dose (4, 4, and 8 mg/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ataluren (PTC124) at higher dose (10, 10, and 20 mg/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ataluren (PTC124)
Number of subjects: 30
Study: 17558098

Group type: EXPERIMENTAL
Intervention: Tinospora cordifolia as an adjuvant therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 50
Study: 16623023

Group type: EXPERIMENTAL
Intervention: Sporal 200 mg twice daily for 1 week
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Itracon 200 mg twice daily for 1 week
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Itra 200 mg twice daily for 1 week
Number of subjects: 133
Study: 12564659

Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg twice daily
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study: 10215286

Group type: EXPERIMENTAL
Intervention: MR-echo score in patients who developed severe MR (10.5 +/- 1.4)
Number of subjects: 117

Group type: COMPARATOR
Intervention: MR-echo score in patients who did not develop severe MR (8.2 +/- 1.1)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Anterior leaflet score in severe MR group (2.9 +/- 0.5)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Posterior leaflet score in severe MR group (2.6 +/- 0.7)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Commissures score in severe MR group (2.4 +/- 0.8)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Subvalvular apparatus score in severe MR group (2.6 +/- 0.5)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: MR-echo score cut-off point > or = 10
Number of subjects: 117
Study: 8682088

Group type: EXPERIMENTAL
Intervention: Immunosuppressive therapy plus conventional drug therapy for congestive heart failure
Number of subjects: 111

Group type: COMPARATOR
Intervention: Conventional therapy only
Number of subjects: 111
Study: 1320131

Group type: COMPARATOR
Intervention: CAV regimen (cyclophosphamide 1000 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2 every 3 weeks)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Menogaril (200 mg/m2 every 4 weeks)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Salvage chemotherapy (etoposide 120 mg/m2 on days 1, 2, and 3 and cisplatin 60 mg/m2 on day 1, repeated every 3 weeks)
Number of subjects: 86

Group type: COMPARATOR
Intervention: CAV
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Menogaril
Number of subjects: 86
Study: 6325313

Group type: EXPERIMENTAL
Intervention: Preparation A (bovine fibrinolysin and desoxyribonuclease, no antibiotic)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Preparation B (clostridiopeptidase and chloramphenicol)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Preparation C (trypsin and framycetin sulphate)
Number of subjects: 258
Study: 31519328

Group type: EXPERIMENTAL
Intervention: Patient-Specific Instrument (PSI)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Robotic system
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional instruments
Number of subjects: 30
Study: 28948366

Group type: EXPERIMENTAL
Intervention: G/P (glecaprevir/pibrentasvir) 300/120 mg once daily for 8 weeks
Number of subjects: 167

Group type: COMPARATOR
Intervention: OBV/PTV/r (ombitasvir/paritaprevir/ritonavir) 25/150/100 mg for 12 weeks
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: G/P (glecaprevir/pibrentasvir) 300/120 mg once daily for 12 weeks
Number of subjects: 167
Study: 27138447

Group type: EXPERIMENTAL
Intervention: Self-reported mammography screening data
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Self-reported data on mammography
Number of subjects: 192
Study: 24721127

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) combined with standard hydration
Number of subjects: 76

Group type: COMPARATOR
Intervention: Sham preconditioning combined with standard hydration
Number of subjects: 76
Study: 23403419

Group type: EXPERIMENTAL
Intervention: Tigecycline 50 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tigecycline 200 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 48
Study: 20171036

Group type: EXPERIMENTAL
Intervention: Sirolimus-Eluting Stent (SES)
Number of subjects: 607

Group type: COMPARATOR
Intervention: Coronary Artery Bypass Graft (CABG)
Number of subjects: 607

Group type: COMPARATOR
Intervention: Bare-Metal Stenting (BMS)
Number of subjects: 607
Study: 17588292

Group type: EXPERIMENTAL
Intervention: Perceived behavioural control
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Self‐efficacy
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Locus of control
Number of subjects: 203
Study: 16750022

Group type: EXPERIMENTAL
Intervention: 7.5 mg x m(‐2) YH‐16
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 15 mg/m(2) YH‐16
Number of subjects: 60
Study: 14500805

Group type: EXPERIMENTAL
Intervention: Parathyroid hormone (40 microg subcutaneously daily)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Combination therapy (Parathyroid hormone + Alendronate)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Alendronate (10 mg daily)
Number of subjects: 83
Study: 10768519

Group type: EXPERIMENTAL
Intervention: Amoxycillin/clavulanate 45/6.4 mg/kg/day twice-daily (b.d.)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Amoxycillin/clavulanate 40/10 mg/kg/day three-times-daily (t.d.s.)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Amoxycillin/clavulanate twice-daily (b.d.)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Amoxycillin/clavulanate three-times-daily (t.d.s.)
Number of subjects: 324
Study: 8620818

Group type: EXPERIMENTAL
Intervention: Long-term oral acyclovir (600-800 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No prophylactic therapy (group B)
Number of subjects: 20
Study: 2666140

Group type: EXPERIMENTAL
Intervention: Cromakalim 1 mg as a single daily oral dose for 5 days
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cromakalim in vitro
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 227420

Group type: EXPERIMENTAL
Intervention: halofenate
Number of subjects: 14
Study: 30141699

Group type: EXPERIMENTAL
Intervention: Soong classification for volar locking plate placement
Number of subjects: 6
Study: 31223121

Group type: EXPERIMENTAL
Intervention: Targeted knowledge translation (KT) intervention delivered through the McMaster Optimal Aging Portal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeted knowledge translation (KT) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 28032271

Group type: EXPERIMENTAL
Intervention: CBT-based treatment for Specific Phobias
Number of subjects: 117
Study: 26541919

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 1212

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 1212
Study: 23799751

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (oxygen-air mixture)
Number of subjects: 80